Acumen Pharmaceuticals Lands Series A Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=e5dfb42d-fa5c-40dd-9e62-a0e4ffa005ab&Preview=1 - Date
4/27/2013 - Company Name
Acumen Pharmaceuticals - Mailing Address
4435 North First Street Livermore, CA 94551 - Company Description
Acumen Pharmaceuticals, Inc. is a biotechnology company developing disease modifying medicines and diagnostics for Alzheimer’s disease. Acumen Pharmaceuticals Inc. is engaged in the discovery and development of therapeutics and diagnostics related to soluble Aß oligomers in Alzheimer’s disease. - Website
http://www.acumenpharm.com - Transaction Type
Venture Equity - Transaction Amount
Undisclosed - Transaction Round
Series A - Proceeds Purposes
The capital will fund preclinical and potentially early clinical development of ACU-193, which selectively binds to and captures soluble oligomers of the amyloid-beta peptide. - M&A Terms
- Venture Investor
Undisclosed
